HC Wainwright Reaffirms Buy Rating for IceCure Medical (NASDAQ:ICCM)

HC Wainwright restated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $2.50 price objective on the stock.

Separately, Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

IceCure Medical Trading Down 6.8 %

NASDAQ:ICCM opened at $0.61 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $27.78 million, a price-to-earnings ratio of -1.87 and a beta of 0.48. The firm has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.77. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.57.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Tuesday, August 20th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $0.90 million. IceCure Medical had a negative net margin of 410.22% and a negative return on equity of 111.27%. During the same period last year, the company posted ($0.09) earnings per share. Analysts expect that IceCure Medical will post -0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.